Wits RHI
Clinical Trials team
HPV acquisition and clearance in women randomized to the contraceptives depot medroxyprogesterone acetate, copper intrauterine device, or levonorgestrel implant: a secondary analysis of a randomized clinical trial
HPV acquisition and clearance in women randomized to the contraceptives depot medroxyprogesterone acetate, copper intrauterine device, or levonorgestrel implant: a secondary analysis of a randomized clinical trial
HPV acquisition and clearance in women randomized to the contraceptives depot medroxyprogesterone acetate, copper intrauterine device, or levonorgestrel implant: a secondary analysis of a randomized clinical trial
‘ … they just take one pill, so it is easy to use, more convenient … ’: South African health care provider perspectives on a Dual Prevention Pill
Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study
Recruiting people who inject drugs (PWID) into research: benefits and challenges of respondent driven sampling (RDS) in a sample in KwaZulu-Natal, South Africa
News in Clinical trials
Dr Nkosi Ndlovu describes the twice-yearly injectable as a “groundbreaking…
Dr Nkosiphile Ndlovu is featured as one of the scientists…
Prof Palanee-Phillips, who has dedicated decades to HIV research and…
Footer
Established in 1994, Wits RHI is part of the Faculty of Health Sciences and the leading research institute of the University of the Witwatersrand.